Imugene Limited (ASX:IMU)
Australia · Delayed Price · Currency is AUD 0.0550
-0.0030 (-5.17%)
Sep 11, 2026, 11:29 AM AEST
Imugene Revenue
In the fiscal year ending June 30, 2026, Imugene had annual revenue of 2.09M AUD, down -53.07%. Imugene had revenue of 1.28M in the half year ending June 30, 2026.
Revenue
2.09M
Revenue Growth
-53.07%
P/S Ratio
13.62
Revenue / Employee
149.01K
Employees
14
Market Cap
28.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2.09M | -2.36M | -53.07% |
| Jun 30, 2025 | 4.45M | -524.62K | -10.56% |
| Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
| Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
| Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 13.50M |
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Neurotech International | 4.73M |
| Proteomics International Laboratories | 3.37M |
| Noxopharm | 1.43M |
| Nexsen | 1.09M |
Imugene News
- 14 days ago - Imugene Annual report: H2 2026 - Filings
- 3 months ago - Imugene Slides: Study update presentation - Filings
- 3 months ago - Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU) - GlobeNewsWire
- 4 months ago - Imugene Earnings release: Q3 2026 - Filings
- 6 months ago - Imugene Quarterly report: H1 2026 - Filings
- 7 months ago - Imugene Earnings release: Q2 2026 - Filings
- 9 months ago - Imugene Transcript: FDA Meeting Update - Transcripts
- 9 months ago - Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours - PRNewsWire